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Abstract
Background and Purpose: Standard therapy for soft-tissue sarcomas remains complete resection. For primary 
radiotherapy local control rates of 30-45% have been reported. We analyzed retrospectively 11 cases of 
radiochemotherapy with single-agent ifosfamide in patients with macroscopic soft-tissue sarcomas.
Patients and Methods: The patients were treated in irresectable high risk situations. Radiation therapy was performed 
with median 60 Gy. During the first and fifth week the concomitant chemotherapy with ifosfamide was added. Two 
patients received trimodal therapy with additional regional hyperthermia.
Results: The therapy was completed in 73% of the patients. Average local control time was 91 months, median 
disease-free-survival/overall-survival was 8/26 months. Five-year rates for local control/disease free survival/overall 
survival were 70%/34%/34%. The limited prognosis is mainly caused by systemic treatment failure.
Conclusions: The data strongly suggest a better outcome of radiochemotherapy with ifosfamide compared to 
radiotherapy alone and radiotherapy in combination with other radiosensitizers.
Introduction
Advanced, localized soft tissue sarcomas are still a chal-
lenge for all therapeutic disciplines involved. The multi-
modal therapy consists of surgery, radiotherapy and
chemotherapy [1]. Radiotherapy improves local control
as neoadjuvant and adjuvant approach in many clinical
situations, especially in high grade sarcomas and deep
seated tumours.
Adjuvant chemotherapy is applied by some groups in
selected patients with sarcomas of the extremities in high
risk situations, for example deep location, grade 2 and 3
and size larger than 5 cm [2-4]. Despite all efforts, the
prognosis, especially for advanced high grade sarcomas,
is still limited. In localized disease the therapeutic aim is
to achieve a complete resection as most important prog-
nostic factor for local control and survival. Some authors
even state that only complete, margin-negative resection
can be considered as curative treatment [5].
The question is how to treat patients with localized,
non-resectable tumours. As the disease is not metasta-
sized, a chance for cure can be assumed, but long-term
tumour control could only be achieved with radiation
doses of at least 63 Gy [6]. This dose-response-relation-
ship reveals the difficulty of treatment, because extent of
the tumour and proximity to organs at risk limit the cura-
tive approach especially in retroperitoneal sarcomas.
The first report on a series of 36 irresectable patients
treated with concurrent radiochemotherapy was pub-
lished in 1991. Aggressive treatment in large, irresectable
soft tissue sarcoma showed to be favorable compared to
the application of hypofractionated palliative regimens
[7].
Effective chemotherapeutic regimens were initially
developed for the use in metastatic disease. Considering
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different chemotherapeutic agents, our selection was
geared to the nowadays established first-line chemothera-
peutic approach consisting of anthracyclines and ifosf-
amide [4,8]. Ifosfamide was chosen as radiosensitizer due
to its superior toxicity profile in combination with radio-
therapy [9,10]. This treatment combination was applied
in individual cases without alternative options with the
informed consent of the patients, that it is no standard
regimen.
The aim of our analysis was to evaluate retrospectively
the safety and efficacy of simultaneous radiochemother-
apy with single-agent ifosfamide. To our knowledge, this
is the first approach of definitive ifosfamide-based
radiochemotherapy in patients with localized, irresect-
able soft tissue sarcomas.
Patients and Methods
From 1996 to 2007 eleven patients (four males, seven
females), median age of 55 years, were treated with con-
current ifosfamide and radiotherapy as definitive treat-
ment primarily or after resection with gross residual
tumour. Median follow-up was 55 months ranging from 4
to 131 months.
The tumour characteristics defined a high risk situation
regarding all relevant prognostic parameters. All patients
had sarcomas larger than 5 cm. The tumours were graded
G2 or G3 according to FNCLCC (Fédération Nationale
des Centres de Lutte Contre le Cancer) (73% G3). Five
tumours had maximal initial diameters of more than 10
cm, one of which was partially resected before radiother-
apy resulting in a residual tumour of 4 cm. Thus, four
tumours (36%) were larger than 10 cm before radiother-
apy. Details are summarized in table 1.
The diagnostic work-up included cross-sectional imag-
ing of the tumour region and chest X-ray or computed
tomography to exclude pulmonary metastasis. The
tumours were diagnosed histologically. The treatment
options were coordinated with all disciplines involved
and surgical options were excluded. Routinely WHO
(World Health Organization) performance status and
laboratory parameters including creatinine clearance
were assessed to ensure sufficient organ function for che-
motherapy.
Radiotherapy was planned 2-D (Two-dimensional) or
3-D (Three-dimensional)-conformal. In two cases better
sparing of normal tissue in the head and neck region and
the retroperitoneum was achieved by IMRT (Intensity
Modulated Radiotherapy). Reproducible immobilization
and linear accelerators with 6-15 MV (Mega Voltage)
photons were used in all patients. Median radiation dose
was 60 Gy (range 50.0-72.6). Fractionation schedules
were 1.8 or 2.0 Gy/day, five times a week. Two patients
were treated with hyperfractionated therapy twice-daily.
Total radiation dose was aimed to be 60 Gy or higher,
dose adaptations were made to achieve sparing of organs
at risk. The aim was a safety margin of 2 cm in all direc-
tions. It was reduced in case of respected anatomical bor-
ders or for sparing of dose-limiting organs at risk.
Accepted dose for spinal cord was 45 Gy, for small bowel
45-50 Gy and 12 Gy for at least one kidney.
The cumulative ifosfamide dose of 10 or 15 g/m2 was
administered in two different schedules with 1.0 or 1.5 g/
m2 on five subsequent days in the first and the fifth week.
Two patients received concurrent regional hyperthermia.
Two hyperthermia treatments weekly were prescribed. In
one patient temperature was measured invasively, in one
patient with pelvic manifestation the probe was placed in
rectum, bladder and vagina. One patient discontinued
hyperthermia after the first treatment due to cardiovas-
cular problems. One received 5 treatments of hyper-
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thermia (25-40 min), the application was limited by
severe pain and circulation problems. (Table 2, Figure 1).
Statistical evaluation was performed with SPSS 15.0 to
calculate Kaplan-Meier-plots. Local control, disease free
survival and overall survival were calculated from the
first day of treatment. The comparison of subgroups was
done with Log-rank (Mantle-cox) test.
Results
Median follow up of patients alive was 13 months. Esti-
mated local control rate after 2 and 5 years was 70%. Four
patients were still at risk after 2 years. A plateau was
reached after 22 months. Two of eleven patients had local
relapse in the irradiated area after a time of 6 and 21
months, respectively, after radiation doses of 70.2 Gy and
66 Gy. Six patients (54%) died of metastasized disease.
Estimated disease free survival was 34% at a plateau after
20 months. Median disease free survival was 8 months as
was median metastasis free survival. Median overall sur-
vival was 26 months, the estimated five year-overall sur-
vival was 34%. No deaths occurred later than 38 months
after treatment. At the time of analysis 3 of 11 patients
are still alive and disease free, all of them for more than 5
years (Figure 2).
Radiotherapy could be applied as planned in 9/11 (82%)
of patients. One patient died during therapy due to respi-
ratory failure caused by enlarging tumour of over 20 cm
in the thoracic irradiation field, compressing the lung and
the great vessels. In one case radiotherapy could only be
completed after a major delay of 4 weeks because of local
infectious complications at the tumour site after multiple
surgical procedures and osteosynthesis with revisions.
T h e  s e c o n d  c y c l e  o f  i f o s f a m i d e  w a s  w i t h h e l d  i n  b o t h
patients and due to leucopenia CTC (Common Toxicity
Criteria) grade III in one additional patient. Thus, the
complete regimen was given in 8/11 (73%) of the patients.
Evaluation of skin toxicity was possible for 9 of the
patients, 2 of which had severe reactions CTC grade III/
IV.
Because of the small sample size, a meaningful sub-
group analysis was not possible. However, a trend
towards decreased disease free survival in high grade
tumours was observed (p = 0.37) (table 3).
The two patients experiencing local failure had
tumours with diameters over 10 cm. The patients still at
risk after 2 years all had tumours smaller than 10 cm.
Thus, a trend towards better outcome for the patients
with smaller tumours can be assumed.
Figure 3 shows MRI (Magnetic Resonance Image)- and
CT (Computed Tomography)- scans of a 49-old female
patient treated with a radiation dose of 60 Gy with a
hyperfractionated twice-daily regimen in combination
with ifosfamide and regional hyperthermia after partial
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Figure 1 Treatment Flow Chart. Treatment consisted of five to seven 
weeks of radiotherapy (median total dose 60 Gy) with two courses of 
chemotherapy in the first and fifth week of irradiation. One chemother-
apy course consisted of five applications of 1.0 or 1.5 g/m2 Ifosfamide 
at five subsequent days. For two patients locoregional hyperthermia 
was added.
Duration: 5 – 7 weeks
Irradiation
5 x 1.8-2.0 Gy 
Ifosfamide  
5 x 1.0 / 1.5 g/m²
Figure 2 Survival Data. Overall survival (a), disease free survival (b), 
metastases free survival (c) and local control rate (d) of all analyzed pa-
tients are shown as Kaplan-Meier-estimation. Estimated 5-year-overall-
survival was 34%, disease free survival and metastases free survival 
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resection of a retroperitoneal pleomorphic high grade
sarcoma (stage pT2b N0 M0) at the time of diagnosis and
eight years after therapy. Hyperthermia was planned
twice a week, but had to be discontinued due to circula-
tion problems after the first treatment. Additional che-
motherapy with three courses of ifosfamide and
epirubicin was administered after completion of
radiochemotherapy. At the time of analysis the patient
was alive and well without tumour recurrence. The only
relevant late effect of CTC grade III or higher was a uni-
lateral ureteral stenosis treated with a Double-J-catheter
on the respective side.
Discussion
Radiochemotherapy with single-agent ifosfamide is a fea-
sible treatment scheme for inoperable high-risk patients
with soft tissue sarcomas located in the retroperitoneum
or the head and neck region.
The patients belonged to a high risk group associated
with an unfavorable prognosis due to the presence of neg-
ative prognosticators in soft tissue sarcomas with respect
to location, size, depth of infiltration and grading [11].
Low grade tumours were not included. The most negative
factor was irresectability respectively incomplete resec-
tion. This fact also explains the number of early death
observed in 4 patients.















Leiomyos. HN T2 G3 8 cm 70.0 Gy 7.5 g/m2 Skin toxicity °III 72 72 AWOD
PNET Trunk T2 G3 11 cm 60.0 Gy 15 g/m2 99  D O D
Anaplastic S. Trunk T2 G3 9 cm 60.0 Gy
HF + HT
10 g/m2 124 124 AWOD
Angios. Trunk T2 G2 8 cm 55.6 Gy 5 g/m2 Interruption 
(abscess)
106 106 AWOD
Chondros. Trunk T2 G2 13 cm 66.0 Gy 10 g/m2 Leucopenia 21 LF 30 DOD
Synovials. Trunk T2 G2 25 cm 50.0 Gy 7.5 g/m2 Death during 
therapy
11  D O D
Pleomorphic S. Trunk T2 G3 11 cm 70.2 Gy 10 g/m2 Skin toxicity °III 6 LF 10 DOD
RTCHX after R2-resection
Leiomyos. Trunk T2 G3 15 cm - 4 cm 66.0 Gy
HF + HT
10 g/m2 26 26 DOD
Synovials. Trunk T2 G3 9 cm - 3 cm 50.4 Gy 15 g/m2 13 13 DOD
Rhabdomyos. HN T2 G3 6 cm - 4 cm 72.6 Gy 15 g/m2 Leuco- penia °IV 5 5 DOD
Leiomyos. Trunk T2 G3 11 cm 59.6 Gy 15 g/m2 44  D O D
Abbreviations:
AWOD - Alive without disease
DOD - Dead of disease
HF - Hyperfractionation
HN - Head and neck
HT - Hyperthermia
Ifo - Ifosfamide
LF - Local failure
Mo - Months
PNET - Peripheral neuroectodermal tumor
RT - Radiotherapy
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The use of radiosensitizing agents in patients with soft
tissue sarcomas can be tracked to the late 80 ies, when for
the first time aggressive treatment schedules for irresect-
able soft-tissue sarcomas were investigated [12]. Goffman
et al. described a better outcome and less toxicity for
iododeoxyuridine compared to misonidazole. However,
local control after 3 years was 37%, thus worse than the
here described survival rates [7]. Also the use of razoxane
or continuous administration of doxorubicin was dis-
cussed in the 90 ies [13,14]. Ifosfamide yielded an at least
additional effect in combination with fractionated radio-
therapy in a xenograft model [15]. It was used in com-
bined treatment regimens with multi-drug-therapy plus
irradiation since 1999 [16,17]
Radiotherapy alone yielded no local control after 5
years in retroperitoneal sarcomas [18]. In head and neck
sarcomas, individual cases (1/6 patients) demonstrated a
curative potential of radiotherapy alone [19].
Kepka et al. described radiotherapy without additional
systemic therapy in 112 patients, 33 of whom had
tumours of 10 cm or more before radiotherapy (29%).
11% of the tumours were low-grade sarcomas, the rate of
G3 tumours was 37%. The local control rates were 45%
and 10% for tumours with diameters from 5 to 10 cm and
more than 10 cm respectively after 5 years [20]. Due to
the small patient numbers no separate evaluation could
be performed with our data, but the estimated overall
local control rate of 70% after 5 years in a patient group
with 36% of tumours greater than 10 cm and 73% high
grade sarcomas gives at least indirect evidence that ifosf-
amide improves local control in combination with radia-
tion therapy.
A five-year overall survival of 34% of the patients in this
prognostic group thus compares favorably with historic
controls of radiotherapy alone. The prognosis is deter-
mined by systemic treatment failure as 66% of the
patients developed distant metastases, explaining why
local control only partly translates to overall disease con-
trol. According to the latest meta-analysis concerning
adjuvant chemotherapy in resected soft tissue sarcoma,
an additional doxorubicin and ifosfamide-based chemo-
therapy regimen significantly reduced distant metastases
and mortality in resected sarcomas [21,22]. Therefore,
additional adjuvant chemotherapy might further improve
the outcome in patients receiving definitive radiochemo-
therapy as well.
The results substantiate a considerable long-term
recurrence-free-survival in patients treated with single-
agent ifosfamide radiochemotherapy. Despite of the limi-
tations of the retrospective comparison of different
patient groups and the small case numbers, the data
strongly suggest a better outcome of radiochemotherapy
in combination with ifosfamide compared to radiother-
apy alone and radiotherapy in combination with other
radiosensitizers. The described treatment protocol
should be tested in a greater patient population in order
to generate more reliable data.
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